Treatment of migraines during pregnancy
DOI: 10.32364/2587-6821-2020-4-9-601-605
N.V. Latysheva, E.G. Filatova, N.V. Naprienko
Sechenov University, Moscow, Russian Federation
One in four women of reproductive age suffers from migraines with varying incidence of episodes. Treatment of migraines during pregnancy is a complex problem for doctors and patients. Nowadays, more than 70% of pregnant women receive prescription and over-the-counter medications during pregnancy. At the same time, information about the safety of taking such drugs by pregnant women is commonly not available. That is why doctors and patients use certain medications without a premeditated and coordinated tactics for controlling migraines, commonly making a decision at the beginning of the next episode. The article provides detailed information about the course patterns, as well as the rules for managing migraines during pregnancy. The article also describes the recommendations for developing an optimal tactics for relieving seizures and preventive therapy. Following these recommendations will allow patients to adequately prepare for pregnancy, avoid taking unsafe medications, while maintaining optimal control over the incidence and duration of migraine episodes during this critical period.
Keywords: migraine, pregnancy, seizure prevention, preventive treatment, sumatriptan, neurostimulation.
For citation: Latysheva N.V., Filatova E.G., Naprienko N.V. Treatment of migraines during pregnancy. Russian Medical Inquiry. 2020;4(9):601–605. DOI: 10.32364/2587-6821-2020-4-9-601-605.
Acknowledgment
Editorial Board is grateful to “Sotex” Pharm Firm” for the assistance in technical edition of this publication.
About the authors:
Nina V. Latysheva — Cand. of Sci. (Med.), Associate Professor of the Department of Nervous System Diseases, Sechenov University: 8, bld. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0001-9600-5540.
Elena G. Filatova — Dr. of Sci. (Med.), Professor, Associate Professor of the Department of Nervous System Diseases, Sechenov University: 8, bld. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0001-9978-4180.
Margarita V. Naprienko — Dr. of Sci. (Med.), Professor of the Department of Integrative Medicine, Sechenov University: 8, bld. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0003-4204-2279.
Contact information: Nina V. Latysheva, e-mail: ninalat@gmail.com. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. There is no conflict of interests. Received 28.08.2020, revised 11.09.2020, accepted 25.09.2020.
2. Ayzenberg I., Katsarava Z., Sborowski A. et al. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014;21(5):758–765. DOI: 10.1111/ene.12380.
3. Табеева Г.Р. Менструальная мигрень. РМЖ. 2008;16(4):195–199. [Tabeeva G.R. Menstrual migraine. RMJ. 2008;16(4):195–199 (in Russ.)].
4. Goadsby P.J., Goldberg J., Silberstein S.D. Migraine in pregnancy. BMJ. 2008;336(7659):1502–1504. DOI: 10.1136/bmj.39559.675891.AD.
5. Bushnell C.D., Jamison M., James A.H. Migraines during pregnancy linked to stroke and vascular diseases: US population based case-control study. BMJ. 2009;338:b664. DOI: 10.1136/bmj.b664.
6. Calhoun AH. Migraine treatment in pregnancy and lactation. Curr Pain Headache Rep. 2017;21(11):46. DOI: 10.1007/s11916-017-0646-4.
7. Chou D.E., Shnayderman Yugrakh M., Winegarner D. et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019;39(1):3–14. DOI: 10.1177/0333102418811573.
8. Spielmann K., Kayser A., Beck E. et al. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia. 2018;38(6):1081–1092. DOI: 10.1177/0333102417724152.
9. Evers S., Afra J., Frese A. et al. EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968–981. DOI: 10.1111/j.1468-1331.2009.02748.x.
10. Schoenen J., Vandersmissen B., Jeangette S. et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80(8):697–704. DOI: 10.1212/WNL.0b013e3182825055.
11. Di Fiore P., Bussone G., Galli A. et al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol Sci. 2017;38(Suppl 1):201–206. DOI: 10.1007/s10072-017-2916-7.
12. Riederer F., Penning S., Schoenen J. Transcutaneous supraorbital nerve stimulation (T-SNS) with the Cefaly® device for migraine prevention: a review of the available data. Pain Ther. 2015;4(2):135–147. DOI: 10.1007/s40122-015-0039-5.
13. Wells R.E., Turner D.P., Lee M. et al. Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep. 2016;16(4):40. DOI: 10.1007/s11910-016-0634-9.
14. Parikh S.K., Delbono M.V., Silberstein S.D. Managing migraine in pregnancy and breastfeeding. Prog Brain Res. 2020;255:275–309. DOI: 10.1016/bs.pbr.2020.07.011.
15. Afridi S.K. Migraine: navigating the hormonal minefield. Pract Neurol. 2020;20(2):115–121. DOI: 10.1136/practneurol-2019-002332.
16. Li W., Tang M. Application of botulinum toxin in pregnancy and its impact on female reproductive health. Expert Opin Drug Saf. 2020;19(1):83–91. DOI: 10.1080/14740338.2020.1707803.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать